Alirocumab 300mg adherence study in Italy
Part of Hormones & metabolism clinical trials.
This study tracks how well patients stick to and benefit from alirocumab 300mg, a cholesterol-lowering injection. It looks at real-world use in Italy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently being treated with alirocumab 300mg
- You are between 18 and 80 years old
- You agree to take part and sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two new medications (QCZ484 and inclisiran) designed to lower both blood pressure and cholesterol levels. You may be a good fit if you have high blood pressure and high cholesterol that isn't fully controlled by current treatments.
This study looks at how well people stick with and respond to the cholesterol-lowering drug Inclisiran. It aims to understand if the medicine works well over time in Italian patients.
This study is checking how well people stick with taking bempedoic acid, a cholesterol-lowering medication, and how effective it is over time.
This study tests if a weekly injection of alirocumab (Praluent) is safe and effective for people with high cholesterol. It aims to help lower LDL cholesterol that has not responded enough to current treatment.
This study tests whether a cholesterol-lowering injection (alirocumab) helps people who are on regular dialysis. It aims to improve cholesterol control in a carefully selected group and tracks safety during treatment.
This study follows people who are starting one of three injectable cholesterol medications (inclisiran, evolocumab, or alirocumab) to see how well they stick with treatment over time. Understanding medication adherence helps doctors and patients find ways to improve long-term health outcomes.
Hear when a new Hypercholesterolaemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.